Objective: To review potential clinical situations beyond sepsis in which activated protein C might be an effective treatment.
xperimental studies indicate that impaired function of the protein C (PC) pathway plays a major role in the pathogenesis of sepsis and associated organ dysfunction (1) . In a usually sublethal baboon bacteremia model, blockade of the PC pathway with monoclonal antibodies resulted in 100% mortality (2) . Administration of activated PC (APC) in a sublethal baboon bacteremia model resulted in the survival of all animals receiving treatment, whereas control animals in the same experiment all died (3) . A similar beneficial effect was seen in rabbits with meningococcal endotoxic shock (4) . In humans, clinical trials in patients with sepsis have shown that recombinant human APC (drotrecogin alfa [activated]) decreases mortality. In a dose-ranging clinical trial, patients with sepsis received either drotrecogin alfa (activated), at doses ranging from 12 to 30 g·kg Ϫ1 ·hr Ϫ1 , or placebo (5) . Based on D-dimer plasma levels, the optimal dose of drotrecogin alfa (activated) was determined to be 24 g·kg Ϫ1 ·hr Ϫ1 . There was a clear trend toward a lower mortality rate (a 40% relative risk reduction) in patients receiving higher doses of drotrecogin alfa (activated), although this was not statistically significant (due to the size of the trial). Subsequently, the large, randomized, double-blind, placebocontrolled, multiple center PROWESS trial was prematurely stopped at the second interim analysis because of a significant reduction in mortality in the drotrecogin alfa (activated)-treated patients (6) . Mortality was 24.7% in the drotrecogin alfa (activated) group compared with 30.8% in the placebo group (relative risk reduction, 19.4%; 95% confidence interval, 6. 6 -30.5 ). An extensive analysis of subgroups in this trial demonstrated that administration of drotrecogin alfa (activated) was of benefit in virtually all subgroups, including those defined by age, type and site of infection, and disease severity. As expected, patients treated with drotrecogin alfa (activated) had less organ dysfunction (7, 8) . A recent analysis of the long-term survival of patients in this trial showed that the benefit of drotrecogin alfa (activated) was sustained over time (9) .
Mechanisms of the Beneficial Effect of APC in Sepsis
Under physiologic conditions, PC is activated by thrombin bound to the endothelial-cell-membrane-associated receptor thrombomodulin (TM). The binding of thrombin to TM not only results in an approximately 100-fold increase in the activation of PC, but it also blocks the thrombin-mediated conversion of fibrinogen into fibrin and inhibits the binding of thrombin to other cellular receptors on platelets and inflammatory cells. The binding of PC to endothelial PC receptor results in a further five-fold augmentation of the activation of PC by the thrombin-TM complex (10) . Dysfunction of the PC system in sepsis is the result of a combination of factors, including low levels of PC (due to impaired synthesis (11) and degradation by neutrophil elastase (12) ) and, most notably, down-regulation of TM expression by proinflammatory cytokines. Observations in patients with severe Gram-negative septicemia have confirmed the down-regulation of TM expression and impaired activation of PC in vivo (13) .
APC is a physiologic anticoagulant that modulates coagulation by proteolytically degrading the essential coagulation factors Va and VIIIa. Dysfunction of the PC system may lead to inadequate modulation of tissue factor-mediated thrombin formation, which may contribute to the formation of microvascular thrombosis. This, in turn, impairs the blood supply to various organs and contributes to the cause of organ failure (14) . Indeed, in endotoxemic mice with targeted deletion of one allele of the PC gene (resulting in a heterozygous PC deficiency), the resultant low levels of PC led to increased fibrin deposition (15) . In addition, APC may affect endogenous fibrinolysis by inhibiting the fibrinolytic inhibitor plasminogen activator inhibitor-1. In a rat model of disseminated intravascular coagulation, APC was shown to block plasminogen activator inhibitor-1 activity, and other experiments have shown that APC enhances clot lysis in vivo (16, 17) . The administration of drotrecogin alfa (activated) to patients with sepsis does indeed result in the modulation of coagulation, as evidenced by a significant decrease in plasma D-dimer levels. Also, the presence of severe coagulation abnormalities in patients with sepsis (classified as disseminated intravascular coagulation) determines a subgroup of patients who derive the relatively largest mortality reduction by administration of drotrecogin alfa (activated) (18). Hence, there is ample evidence that APC exerts its beneficial effects in sepsis through its anticoagulant properties.
However, besides its anticoagulant effect, APC also has important inflammation-modulating properties (19, 20) . Indeed, APC has been found to inhibit endotoxin-induced production of tumor necrosis factor-␣, interleukin-1␤, interleukin-6, and interleukin-8 by cultured monocytes/macrophages (21, 22) . It is likely that the effects of APC on inflammation are mediated by the endothelial PC receptor, which may mediate downstream inflammatory processes (19). The binding of APC to the endothelial PC receptor was shown to affect the gene expression profiles of cells by inhibiting endotoxin-induced intracellular calcium fluxes and by blocking nuclear factor-B nuclear translocation, which is a prerequisite for increases in proinflammatory cytokines and adhesion molecules (23, 24) . Blocking the PC pathway or the PC receptor using a monoclonal antibody in septic baboons exacerbates the inflammatory response, as has been evidenced by increased levels of proinflammatory cytokines and more leukocyte infiltration and tissue destruction on histologic analysis (25, 26) . Conversely, the administration of APC ameliorates the inflammatory activation in various models of severe sys-temic inflammation (20, 27) . Mice with targeted deletion of one allele of the PC gene not only have a more severe coagulation response to endotoxin but also demonstrate significant differences in inflammatory responses, as shown by higher levels of circulating proinflammatory cytokines (15) . In the PROWESS trial, interleukin-6 levels were significantly lower in the treatment group, although the results of other cytokine assays were not significant. Nevertheless, the inflammation-modulating properties of APC may certainly be relevant for patients with sepsis.
It is not clear whether the beneficial effect of APC in sepsis is due primarily to its anticoagulant or its anti-inflammatory effects. The dose of drotrecogin alfa (activated) used in the PROWESS trial was based on effects on D-dimer levels in the phase II study (5) , suggesting that the treatment is tailored with respect to its anticoagulant effect. But if this anticoagulant effect is the most important therapeutic feature of drotrecogin alfa (activated), it is not clear why interventions targeting other physiologic anticoagulant pathways in patients with sepsis have not been effective (28, 29) . On the other hand, the significance of the inflammation-modulating properties of APC in vivo is not completely clear, and the antiinflammatory effect of APC in clinical trials is hard to assess (30) . Previous trials have failed to demonstrate benefit with a range of potent anti-inflammatory agents (31) . Hence, the benefit of APC is hard to explain on the basis of either anticoagulant or anti-inflammatory effects alone. Instead, it is most likely that the beneficial effect is due to a combination of anticoagulant and anti-inflammatory properties. In view of the central role of the endothelium in maintaining vascular patency and integrity, the strength of APC might be its capacity to restore the regulation of coagulation and inflammation at the endothelial site.
Potential Benefit of APC in Other Clinical Settings
It is tempting to speculate that other clinical situations that are characterized by endothelial dysfunction and microvascular failure might benefit from the administration of drotrecogin alfa (activated). Therefore, it can be envisaged that APC might play a prominent role in ischemia-reperfusion syndromes. Virtually every organ can suffer from ischemia-reperfusion injury, which often plays an important role in major clinical entities such as myocardial infarction, acute renal failure, stroke, acute lung injury, and intestinal ischemia. Ischemia-reperfusion injury is characterized by a local inflammatory response and local activation of coagulation, reminiscent of the systemic situation in sepsis (32, 33) . In addition to ischemia-induced cell necrosis, apoptosis may also play a role (34) . APC has also been reported to possess anti-apoptotic properties (35) .
Role of the PC System in Ischemia-Reperfusion Injury
Renal ischemia-reperfusion syndromes are characterized by tubular necrosis and glomerular thrombosis. The fact that the PC system plays an important role in preventing glomerular thrombosis may be inferred from the abundant presence of TM expression on endothelial cells in the glomerulus (36) . An increase in TM expression has been observed in inflammatory glomerular diseases such as acute membranoproliferative and lupus glomerulonephritis (37) . In contrast, TM expression is markedly down-regulated in ischemia-reperfusion injury in kidneys. Administration of soluble TM to rats with renal ischemiareperfusion injury has been shown to prevent massive glomerular thrombosis and kidney dysfunction (38) . In another experimental study of renal ischemia and reperfusion in rats, administration of APC prevented histologic changes and the ischemia-reperfusion-induced decrease in renal blood flow while preserving kidney function, whereas treatment with active-site-blocked factor Xa, heparin, or inactivated PC was less effective (39) . APC also attenuated the ischemiareperfusion-associated increase in renal levels of inflammatory cytokines tumor necrosis factor-␣ and interleukin-8 and in renal myeloperoxidase activity, whereas other interventions had no such effect. In this same model, renal injury could also be prevented by rendering rats leukocytopenic (by administering nitrogen mustard), further supporting the notion that APC has anti-inflammatory effects (39) . It is interesting to note that, in contrast, in sepsis-induced renal changes, no effect on TM expression and PC activation was found (40) .
Marked down-regulation of TM and the endothelial PC receptor has been demonstrated on endothelial cells overly-ing the atherosclerotic plaque in coronary arteries of patients with severe atherosclerosis, suggesting a role for the PC system in acute coronary syndromes (41) . Administration of APC prolonged the time to occlusion and improved vessel patency and myocardial blood flow in a canine model of coronary artery thrombosis and reperfusion (42) . In coronary artery reperfusion during heart surgery, activation of PC was shown to be related to the regulation of inflammatory activity (43) . In this study, levels of APC were negatively correlated with myeloperoxidase activity and L-selectin expression on neutrophils. Together, these observations suggest that the PC system is likely to play a role in coronary artery syndromes and myocardial reperfusion injury.
Abundant intravascular and extravascular fibrin is a histologic hallmark of acute lung injury (44) . Experimental and clinical studies have shown that fibrin deposition is due to tissue-factor-mediated thrombin generation and suppressed fibrinolysis (45, 46) . In recent experiments, the activation of bronchoalveolar coagulation in severe pneumonia was shown to be restricted to the site of acute lung injury (47) . In these same series of experiments, a significant reduction in bronchoalveolar PC activation was observed, as was evidenced by low levels of PC and APC in lavage fluids from patients with community-acquired and ventilatorassociated pneumonia. Similar findings were reported in a study of patients with acute lung injury and adult respiratory distress syndrome (48) . The decrease in PC activation in both studies was strongly correlated with high levels of soluble TM in the bronchoalveolar fluid, suggesting that shedding of TM caused the inability to activate PC and that the PC system may also be involved in acute lung injury.
In experimental models, acute intestinal ischemia and reperfusion can result in impaired intestinal structure and func-tion characterized by intestinal cell swelling, protein leakage, and impaired intestinal absorptive capacity. In addition, intravascular and extravascular fibrin deposits may be present due to activation of mesenteric coagulation and inhibition of fibrinolysis (49) . Within 20 -40 mins of occlusion of the superior mesenteric artery, and subsequent reperfusion, portalvein plasma levels of thrombin-antithrombin increased, indicating local thrombin generation. This increase in portal coagulation activity is associated with a marked fall in PC activity levels. Simultaneously, markers for fibrinolysis in portal plasma showed complete inhibition due to an increase in levels of plasminogen activator inhibitor-1. This activation of coagulation on ischemiareperfusion could be almost completely blocked by systemic administration of APC, whereas heparin and antithrombin were less effective (I. G. Schoots et al., unpublished observations). Interestingly, amelioration of ischemia-reperfusioninduced intestinal intravascular and extravascular fibrin deposition by administration of APC caused a significant improvement in intestinal function.
Conclusion
Taken together, the evidence supports an interesting role for the PC system in ischemia-reperfusion injury. Consequently, administration of drotrecogin alfa (activated) might be a promising therapeutic option in these situations. The efficacy of the approach deserves further research in experimental and clinical studies. intravascular coagulation induced by lipopolysaccharide in rats. 
